SurModics Drops to Neutral Zacks.com Moreover, we are also mindful of setbacks such as Johnson & Johnson's (JNJ) decision to stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents from which SurModics earned royalties. Setbacks of a similar nature will ... |
